Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448693 | 1.00 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL14448692 | 1.00 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL4434977 | 0.92 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL16295146 | 0.88 | — | — | |
| SCHEMBL16294338 | 0.88 | — | — | |
| SCHEMBL20483089 | 0.88 | — | — | |
| SCHEMBL9284273 | 0.88 | — | — | |
| SCHEMBL12884770 | 0.85 | MEN1 (0.35) | ALDH1A1 | |
| SCHEMBL823000 | 0.85 | — | — | |
| SCHEMBL294098 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241004-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE POLYMER | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20180193285-A1 | Rivastigmine Transdermal Compositions and Methods of Using the Same | TEIKOKU PHARMA USA, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9949935-B2 | Rivastigmine transdermal compositions and methods of using the same | TEIKOKU PHARMA USA, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150283097-A1 | Rivastigmine Transdermal Compositions and Methods of Using the Same | TEIKOKU PHARMA USA, INC. | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283097-A1 | Rivastigmine Transdermal Compositions and Methods of Using the Same | ACHE, CHRNE, CHRNA7 | ALDH1A1 2903/4885 |
| US-20180193285-A1 | Rivastigmine Transdermal Compositions and Methods of Using the Same | ACHE, CHRNE, CHRNA7 | ALDH1A1 2903/4885 |
| US-20230241004-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE POLYMER | PDE2A, PDE3A, PDE3B | ALDH1A1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.